Results 261 to 270 of about 419,158 (294)
Some of the next articles are maybe not open access.
2010
?? ?????????? ?????????????? ?????????????????????????????? ?????????? ?????????????????????? ???????? ?????????????????????? ???????????????????????? ???????? ?????????????? ???????????????????????????????? ?????????? ?????????????????????????????????? ???????????????????? ??Pfizer?? ?????????????????????????? ???????? ???????????? ???? ???????????????
openaire +1 more source
?? ?????????? ?????????????? ?????????????????????????????? ?????????? ?????????????????????? ???????? ?????????????????????? ???????????????????????? ???????? ?????????????? ???????????????????????????????? ?????????? ?????????????????????????????????? ???????????????????? ??Pfizer?? ?????????????????????????? ???????? ???????????? ???? ???????????????
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2001
Pfizer is developing pregabalin, a follow-up compound to its GABA agonist gabapentin, for the potential treatment of several central nervous system (CNS) disorders including epilepsy, neuropathic pain, anxiety and social phobia [286425]. By December 2000, Pfizer anticipated filing an NDA for pregabalin for seven major indications (beginning with ...
openaire +1 more source
Pfizer is developing pregabalin, a follow-up compound to its GABA agonist gabapentin, for the potential treatment of several central nervous system (CNS) disorders including epilepsy, neuropathic pain, anxiety and social phobia [286425]. By December 2000, Pfizer anticipated filing an NDA for pregabalin for seven major indications (beginning with ...
openaire +1 more source
IIC - International Review of Intellectual Property and Competition Law, 2014
openaire +1 more source
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2002
Gabapentin has been approved for the treatment of neuropathic pain in six European countries, New Zealand and Australia, and numerous countries in Latin America. By January 2001, Pfizer was preparing to file an NDA in the US for this indication; by October 2001, this NDA had been filed with the FDA. The drug is a GABA analog, but is not a GABA mimetic,
openaire +1 more source
Gabapentin has been approved for the treatment of neuropathic pain in six European countries, New Zealand and Australia, and numerous countries in Latin America. By January 2001, Pfizer was preparing to file an NDA in the US for this indication; by October 2001, this NDA had been filed with the FDA. The drug is a GABA analog, but is not a GABA mimetic,
openaire +1 more source
A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson
Human Vaccines and Immunotherapeutics, 2022Payal Kahar, Deepesh Khanna
exaly
Pfizer’s small-molecule antiviral misses on COVID prevention
Nature Reviews Drug Discovery, 2022exaly